AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01972204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive adherence instruction
Description: Instruction with educational brochure
Study NCT01972204 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Instruction as per usual practice
Study NCT03962348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Early Engagement Support Service
Description: The Specialized Early Engagement Support Service (SEESS - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
Study NCT03109132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oridion Smart CapnoLine® H Plus with Wedge cannula
Description: The subjects will assess the comfort level of the different cannulas
Study NCT03109132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oridion Smart CapnoLine® Plus with Non-Wedge cannula
Description: The subjects will assess the comfort level of the different cannulas
Study NCT03109132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental sample line Model 3
Description: The subjects will assess the comfort level of the different cannulas
Study NCT03109132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental sample line Model 4
Description: The subjects will assess the comfort level of the different cannulas
Study NCT03109132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental sample line Model 5
Description: The subjects will assess the comfort level of the different cannulas
Study NCT03109132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
Description: The subjects will assess the comfort level of the different cannulas
Study NCT00546897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT00715377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine
Description: Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
Study NCT04236960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group ACYW135 Conjugate Vaccine
Description: 1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)
Study NCT03756493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Surgery OFD
Description: Patients will be treated by Open Flap Debridement without use of filling material.
Study NCT02087267 — intervention group
Intervention type: PROCEDURE
Intervention: 1- or 2-level spinal fusion
Description: 1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
Study NCT02925416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Description: Administered intravenously
Study NCT02925416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oritavancin
Description: Administered intravenously
Study NCT02925416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (D5W)
Description: Administered intravenously
Study NCT04925856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: •Blood sample:~* 1 heparinized tube (4 mL) for collection of plasma and storage~* 1 heparinized tube (4 mL) for immunophenotyping,~* 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation.
Study NCT05239429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation Technique
Description: Participants receive one-on-one training on how to use Transcendental Meditation technique which is then practiced twice daily for approximately 20 minutes.
Study NCT05464953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
Study NCT05464953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formulated Triamcinolone
Description: Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
Study NCT01517360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 40 IU, intranasal inhalation
Study NCT01517360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, matched to Oxytocin, intranasal inhalation
Study NCT01517360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Skills Training
Description: The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
Study NCT01517360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognitive Skills Training
Description: The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
Study NCT00613912 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: * Morphological sequences~* Arterial Spin Labelling (Perfusion)~* Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter
Study NCT01022008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteodistraction techniques
Description: Treatment based on craniofacial osteotomies and osteodistraction techniques.
Study NCT04618510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEED 1-dayPure EDOF soft contact lens
Description: Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
Study NCT04618510 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Single Vision Spectacles
Description: These are the type of glasses that correct vision for a single distance
Study NCT03380156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVS
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
Study NCT03380156 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TVS
Description: Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
Study NCT02862509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide nasal instillation
Study NCT03632486 — intervention group
Intervention type: OTHER
Intervention: Bedside Ultrasound
Description: Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~* Lung ultrasound to assess for pleural effusions and sonographic b lines.
Study NCT01323855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
Study NCT03697135 — intervention group
Intervention type: BEHAVIORAL
Intervention: Respondent Driven Sampling
Description: Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
Study NCT03970980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen (FIO2)
Description: Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
Study NCT03970980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fraction of inspired oxygen (FIO2)
Description: Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
Study NCT02188901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sonazoid-enhanced ultrasonography
Description: Sonazoid (perflubutane) \[GE healthcare\]
Study NCT02691871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg/d) + Docetaxel (60 mg/m2)
Study NCT02691871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg/d) + Docetaxel (60 mg/m2)
Study NCT02691871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
Study NCT00830908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HairMax LaserComb
Description: LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
Study NCT04727021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg tablet rivaroxaban
Description: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
Study NCT04727021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg rivaroxaban, granules for oral suspension
Description: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
Study NCT02870023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Study NCT02870023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Study NCT04135105 — intervention group
Intervention type: OTHER
Intervention: Normal hearing group
Description: Observational
Study NCT03911687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONCERN CDS system notification
Description: The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months
Study NCT01414920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Study NCT01414920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01414920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01414920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01414920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875 and Sitagliptin
Description: TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Study NCT01414920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875 and Sitagliptin
Description: TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Study NCT03489746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICS withdrawal protocol
Description: A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
Study NCT03489746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Normal clinically indicated inhaled therapy
Study NCT03498053 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marlboro
Description: Participants smoke Marlboro during the first experimental day, ad libitum.
Study NCT03498053 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marlboro Prime
Description: Participants smoke Marlboro Prime during the second experimental day, ad libitum.
Study NCT03498053 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marlboro Prime (ventilation holes taped)
Description: Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
Study NCT01129193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Studies
Description: Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3.
Study NCT01129193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Inventory
Description: Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
Study NCT01129193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic studies
Description: Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
Study NCT01129193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-42
Description: Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
Study NCT03198689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
Study NCT01813994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm1: Statin
Description: Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
Study NCT02862509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline nasal instillation
Study NCT01499407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearWay RX catheter
Study NCT01499407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Study NCT04323592 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Description: Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 > 350 mmHg or a CRP \< 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to \< 20% of normal range and/or PaO2:FiO2 > 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.
Study NCT04323592 — intervention group
Intervention type: OTHER
Intervention: standard care
Description: usual standard of care:~* oxygen therapy (regular or high-flow) and monitoring~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)~* ECMO when needed and available~* pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins
Study NCT03243630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV nicotine
Description: Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
Study NCT03625674 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: explanation when prescribing psychoactive medicine
Description: explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
Study NCT03243630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV nicotine
Description: Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
Study NCT03243630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Menthol flavor
Description: American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
Study NCT02868827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
Study NCT02868827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk (Nestle)
Description: 45 ml of Nestle milk will given to patients assigned as placebo
Study NCT03141996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration to upper posterior neck muscles
Description: Vibration to upper posterior neck muscles using a vibrational tool.
Study NCT03141996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment
Study NCT00543244 — intervention group
Intervention type: DRUG
Intervention: Pegylated interferon alfa and ribavirin
Description: Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: \< 75 kg 1000 mg/day, >=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)
Study NCT05094973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere Motion Appliance®
Description: To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
Study NCT00345332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Injected
Study NCT00345332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected
Study NCT00911885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.